Researchers claim that pharmaceutical company GlaxoSmithkline has tried to influence the debate on the safety of diabetes treatment drug Avandia, also known as rosiglitazone, which the company manufactures. A new study claims that more than nine out of ten scientists who backed the drug had financial links to the pharmaceutical industry. Researchers from the Mayo Clinic in Minnesota analysed more than 200 articles published in scientific journals, including original papers, editorials and letters, which commented on the heart attack risk associated with Avandia after 2007...
More...
More...